Aging
Navigate
Research Paper|Volume 8, Issue 2|pp 231—244

Reversal of phenotypes of cellular senescence by pan-mTOR inhibition

Hannah E. Walters1, Sylwia Deneka-Hannemann1,2, Lynne S. Cox1
  • 1Department of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, United Kingdom
  • 2Oxford BioMedica Plc, Oxford, OX4 6LT, United Kingdom
Received: July 1, 2015Accepted: January 15, 2016Published: February 5, 2016

Copyright: © 2016 Walters et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Cellular senescence, a state of essentially irreversible proliferation arrest, serves as a potent tumour suppressor mechanism. However, accumulation of senescent cells with chronological age is likely to contribute to loss of tissue and organ function and organismal aging. A crucial biochemical modulator of aging is mTOR; here, we have addressed the question of whether acute mTORC inhibition in near-senescent cells can modify phenotypes of senescence. We show that acute short term treatment of human skin fibroblasts with low dose ATP mimetic pan-mTORC inhibitor AZD8055 leads to reversal of many phenotypes that develop as cells near replicative senescence, including reduction in cell size and granularity, loss of SA-β-gal staining and reacquisition of fibroblastic spindle morphology. AZD8055 treatment also induced rearrangement of the actin cytoskeleton, providing a possible mechanism of action for the observed rejuvenation. Importantly, short-term drug exposure had no detrimental effects on cell proliferation control across the life-course of the fibroblasts. Our findings suggest that combined inhibition of both mTORC1 and mTORC2 may provide a promising strategy to reverse the development of senescence-associated features in near-senescent cells.